Development of more effective influenza A virus vaccines which will gain wider acceptance with populations at risk for influenza A virus-related complications than the currently licensed inactivated virus vaccine is a desirable goal. During recent influenza epidemics in the United States, influenza resulted in an average of 20,000 excess deaths per year (35) . However, in a 1987 population-based survey of influenza immunization levels among U.S. adults in 32 states, only 32.2% of adults aged -65 years had received standard influenza vaccination in the previous 12 months and other data suggest the rate of vaccination to be lower (8) . Administration of a live-attenuated influenza A virus vaccine intranasally offers the advantages of a preferred route of administration and induction of nasal secretory antibody. Murine studies suggest that live-attenuated virus vaccines induce an influenza A virus-specific cytotoxic T-cell response which is cross-protective and cross-reactive among influenza A virus subtypes, but a lack of cross-reactivity and lower levels of cytotoxic T-cell activity result from inactivated virus vaccine injection (34) .
Evidence that cell-mediated immunity plays a role in the reduction of severity of illness and recovery from influenza A virus infection is based on murine and human studies. Adoptive transfer of influenza A virus-specific murine cytotoxic T cells and of influenza-immune T cells to syngeneic mice limit influenza A virus replication in lung tissue of the recipient mice and reduce mortality (21, 31, 38) . Preexisting influenza A virus-specific memory cytotoxic T-cell activity correlates with accelerated viral clearance after wild-type influenza A virus challenge of young adults (23) .
In this study, we immunized older, chronically ill volunteers with either live-attenuated influenza A virus or with monovalent inactivated influenza A subvirion vaccine to determine which preparation induced the better anti-influenza cytotoxicity in vitro postvaccination. We hypothesized that the live-attenuated influenza A virus infection would induce a higher level of cytotoxicity and a response crossreactive among influenza A virus subtypes compared with that of the inactivated virus vaccine.
MATERIALS AND METHODS
Vaccines. The cold-recombinant, live-attenuated influenza A/Korea/1/82 (H3N2) virus vaccine was derived from coldadapted influenza A/Ann Arbor/6/60 virus by H. F. Maassab using methods previously described (9) . The resulting coldrecombinant virus (CR-59, lot numbers E-204 and E-223) contained six genes that code for internal proteins from the donor cold-adapted strain and genes that code for hemagglutinin (HA) and neuraminidase derived from influenza A/Korea/1/82 (H3N2) virus. In addition to being cold adapted, the vaccine virus was temperature sensitive (restrictive temperature, 39°C). The inocula of H3N2, CR-59 vaccine virus were 1072 for lot E-204 and 107 5 for lot E-223 (undiluted as provided by the National Institute of Allergy and Infectious Diseases, Bethesda, Md.) PFU/0.5-ml intranasal dose.
The inactivated monovalent influenza A/Taiwan/1/86 (HlN1) subvirion vaccine (Connaught Laboratories, Inc., Swiftwater, Pa.; lot number 4624) contained 15 Fug of Hi hemagglutinin (HA) per dose and included a mixture of other influenza A/Taiwan/1/86 (HlN1) proteins, including neuraminidase and internal viral proteins. A monovalent subvirion vaccine of an H3N2 subtype would have been the preferable preparation but was not available to us from the manufacturer.
Clinical studies and selection of patients. Volunteers were recruited from a Veterans Affairs population of older, chronically ill adults who were ambulatory and not institutionalized. Inclusionary criteria were the presence of significant chronic obstructive pulmonary disease (COPD), other chronic medical illness, and age over 55 years. Volunteers were not excluded if there was preexisting antibody to Hi and H3 HA or a history of parenteral trivalent inactivated influenza virus vaccination in a previous influenza virus season at least 9 months prior to entry into our study. None had previously been vaccinated with a live-attenuated, coldrecombinant influenza A virus vaccine.
The protocol for clinical studies was approved by the Human Subjects Committee of the Huntington Veterans Affairs Medical Center, Huntington, W.Va., where the study was conducted. The study was conducted in the summer and fall seasons prior to the influenza season. The first group of volunteers was intranasally inoculated with live-attenuated influenza A/Korea (H3N2) CR-59 virus vaccine as previously described (14) . Subsequently, monovalent inactivated influenza A/Taiwan/l/86 (HlNi) virus subvirion vaccine was administered intramuscularly in the deltoid muscle to a second group of volunteers recruited and enrolled into the study after the first group. Volunteers gave written informed consent.
Standard spirometry was performed in the clinical pulmonary function testing laboratory before and 10 to 14 days after vaccination with both vaccines in the individuals with a history of lung disease with a computerized series 2500 Pulmonary Function Laboratory (Gould, Dayton, Ohio) using previously described methods (14) . The forced expiratory volume (FEV1) and forced vital capacity (FVC) were determined (1, 2) , and the degree of obstruction to airflow was categorized on the basis of the FEV1/FVC (percent).
Nasal wash specimens were obtained before and daily for 4 days after vaccination with CR virus vaccine and were inoculated onto tissue culture cells as previously described (4, 14) .
Serological tests. Nasal wash specimens (20 Hemagglutination inhibition (HAI) antibodies in serum were measured by using whole virus homologous to the vaccine strains in a standard microtiter assay (36) .
The CR-59 vaccine virus was grown in the allantoic cavities of eggs, and the HA was extracted and purified by previously described methods (28 (10, 16, 37) were measured using an IFN--y ELISA similar to that described by Van der Meide et al. (33) Statistical methods. Statistical tests included chi-square analysis with Yates' correction and two-tailed Fisher exact test for two-by-two comparisons. Differences in prevaccination and postvaccination mean percent specific lysis and mean log (IFN--y level), and logarithmically transformed prevaccination serum HAI and IgG reciprocal antibody titers were compared by using the Wilcoxon signed ranks test for paired data and Mann-Whitney U test for independent data samples. Arithmetic means are reported with the standard error of the mean.
RESULTS
Patient population. Fifteen chronicallyill volunteers (mean age, 64.3 ± 1.1 years; range, 57 to 71 years) were evaluated for in vitro PBL anti-influenza cytotoxicity, in vitro PBL IFN--y production, serum and nasal wash anti-HA antibodies, and nasal wash shedding of vaccine virus, before and after intranasal inoculation of CR-59 (H3N2) virus. Seven had severe COPD (FEV1/FVC < 45%), three had moderate COPD (FEV1/FVC = 45 to 59%), three had mild COPD (FEV1/FVC = 60 to 69%), one had small airways disease, and one had normal spirometry. Three volunteers had heart disease requiring chronic chemotherapy, two had neurologic disease (cerebrovascular accident and seizure disorder), two had hypertension, and one each had lung cancer, breast cancer, anemia, diabetes mellitus, and chronic alcohol abuse. Fourteen (93.3%) volunteers were infected by the vaccine virus by criteria including a fourfold rise in serum antibody titer to H3 HA (by ELISA, 9 exhibited rises in measured levels of IgG and IgA to H3 HA, and/or HAI VOL. 28, 1990 antibody), a fourfold rise in nasal wash IgA antibody titer to H3 HA (11 volunteers) , and/or nasal wash shedding of vaccine virus (5 volunteers Anti-influenza cytotoxicity of PBL from influenza A/Taiwan (HINl) virus vaccine recipients. Effector PBL were in vitro stimulated with influenza A/Taiwan (HlNi) virus-infected stimulator PBL. The mean percent specific lysis by these PBL from volunteers with a fourfold rise in serum antibody titer significantly increased 14 days postvaccination against only the HlN1-infected target autologous PBL (Table 3) . There were no significant increases in mean percent specific lysis against the H3N2-virus infected or the control unin- Mean percent specific lysis of H3N2 and HlNi virusinfected autologous target cells did not increase postvaccination when effector PBL were in vitro stimulated with influenza A/Korea (H3N2) virus (Table 4) . Thus, increased levels of crossreactive memory anti-influenza cytotoxicity were not induced by the inactivated virus vaccine. For all influenza A/Taiwan (HlNi) vaccinees, the prevaccination and postvaccination mean minimum release of radiolabel as a percentage of mean maximum release were similar for each target cell population (H3N2 infected, prevaccination, 27.7%, 14 and 28 days postvaccination, 28.5 and 24.9%; HlNi infected, prevaccination, 29.7%, 14 and 28 days postvaccination, 28.5 and 27.3%; uninfected, prevaccination, 19.6%, 14 and 28 days postvaccination, 24.5 and 23.2%). Thus, it is unlikely that the observed changes in percent specific lysis postvaccination were due to variability in the assay caused by differences in minimum (spontaneous) 51Cr release as a proportion of maximum release.
Changes in the proportion of vaccinees with specific levels of anti-influenza cytotoxicity postvaccination. Of the 14 volunteers infected with CR-59 virus, percent specific lysis of H3N2 virus-and HlNi-virus infected autologous targets by H3N2 virus-stimulated PBL minus percent specific lysis of control uninfected targets was greater than 10% against both target populations measured prevaccination in 3 (21%) volunteers each and was greater than 10% against both target cell populations when measured 14 or 28 days postvaccination in 12 (86%) volunteers each, (P < 0.001, comparing postvaccination with prevaccination proportions). Percent specific lysis of H3N2 virus-and HlNi virus-infected autologous targets by H3N2 virus-stimulated PBL minus percent specific lysis of control uninfected targets was greater than 20% measured prevaccination in 2 (14%) and 1 (7%) volunteers, respectively, and was greater than 20% when measured at 14 or 28 days postvaccination in 8 (57%) and 9 (64%) volunteers, respectively (P < 0.05 and P < 0.01, comparing postvaccination with prevaccination proportions).
Of the 11 volunteers with a fourfold nasal wash antibody titer rise to H3 HA after CR-59 virus inoculation, percent specific lysis of H3N2 virus-and HlNi virus-infected autologous targets by H3N2 virus-stimulated PBL minus percent specific lysis of control uninfected targets was greater than 10% measured prevaccination in 1 (9%) and 3 (27%) volunteers, respectively, and was greater than 10% when measured 14 days and/or 28 days postvaccination in 10 (91%) and 10 (91%) volunteers, respectively (P < 0.01 and P < 0.01, comparing postvaccination proportions with prevaccination). Percent specific lysis of H3N2 virus-and HlNi virus-infected autologous targets by H3N2 virus-stimulated PBL minus percent specific lysis of control uninfected targets was greater than 20% against both target cell populations measured prevaccination in one (9%) volunteer each and was greater than 20% against both target cell populations when measured at 14 or 28 days postvaccination in eight (73%) volunteers each (P < 0.01, comparing postvaccination proportions with prevaccination). Of the seven volunteers who received the inactivated influenza A virus vaccine, percent specific lysis of HlNl virus-and H3N2 virus-infected autologous targets by HlNl virus-stimulated PBL minus percent specific lysis of control uninfected targets was greater than 10% measured prevaccination in two (29%) and three (43%) volunteers, respectively, and was greater than 10% when measured at 14 or 28 days postvaccination in six (86%) and four (57%), respectively. Percent specific lysis of HlNl virus-and H3N2 virus-infected autologous targets by HlNl virus-stimulated PBL minus percent specific lysis of control uninfected targets was greater than 20% measured prevaccination in one (14%) and 2 (29%) volunteers, respectively, and was greater than 20% when measured at 14 or 28 days postvaccination in four (57%) and three (43%) volunteers, respectively. Of the five inactivated virus vaccinees with a fourfold serum antibody titer rise to Hi HA postvaccination, percent specific lysis of HlNl virus-and H3N2 virus-infected autologous targets by HlNl virus-stimulated PBL minus percent specific lysis of control uninfected targets was greater than 10% measured prevaccination in zero (0%) and two (40%) volunteers, respectively, and was greater than 10% when measured at 14 or 28 days postvaccination in four (80%) and two (40%) volunteers, respectively (P < 0.05 and not significant, comparing postvaccination with prevaccination proportions).
Thus, the proportion of CR-59 virus vaccinees with a higher level of percent specific lysis against autologous targets infected with virus homologous and heterosubtypic to CR-59 virus minus percent specific lysis of control uninfected targets increased significantly postvaccination. The proportion of inactivated virus vaccinees with a higher level of percent specific lysis against autologous targets infected with virus homologous to vaccine virus minus control uninfected target lysis increased postvaccination; however, there was no increase against autologous targets infected with virus heterosubtypic to the subvirion vaccine virus minus control uninfected target lysis.
HLA class I restriction of cytotoxicity. HLA restriction was studied utilizing PBL effectors from 11 vaccinees, seven of whom received the CR-59 virus vaccine and four the inactivated influenza A/Taiwan (HlNl) subvirion vaccine. These studies were done whenever adequate numbers of effector cells were available to measure cytotoxicity against HLA class I mismatched in addition to autologous target PBL. In general, when percent specific lysis of autologous target cells by effector cells obtained both pre-and postvaccination was greater than approximately 12%, the percent specific lysis of the HLA class I mismatched target cells was lower (Tables  5, 6 , and 7). This was also generally true whether the effector cells were in vitro induced with H3N2 or HlNl virusinfected stimulator cells. When the percent specific lysis of autologous target PBL was less than 12%, the lysis of HLA-mismatched target cells was similar in magnitude. This suggests that the underlying background nonspecific target cell lysis was between 0 and 12%. This is consistent with the level of mean percent specific lysis of uninfected autologous target cells, which was less than 10% (Tables 1, 2, 3, and 4) . The number of effector cells available did not allow measurement of lysis of HLA-mismatched, uninfected target cells by heterologous effector cells. Therefore, these control values could not be included in Tables 5, 6 , and 7. Effector PBL from vaccinees sharing one locus at HLA-A2, HLA-A28, or HLA-B8 with target PBL from other vaccinees did not lyse the mismatched target cells to the same degree as autologous targets (Table 6 ). The percent reduction in percent specific lysis of mismatched targets sharing one of these three HLA class I loci compared with lysis of autologous targets ranged from 34 to 100% (Table 6 ). Cytotoxicities of PBL from vaccinees sharing three HLA loci (HLA-B8, 38, and Cw7) differed with respect to HLA restriction (Table 7) . Effector PBL from the vaccinee with HLA-A1,30 lysed autologous target cells more efficiently than the heterologous targets from the vaccinee with HLA-A24,28; however, effector PBL from the HLA-A24,28 vaccinee lysed the HLA-A1,30 target cells to the same degree as autologous cells (Table 7) . This does not appear to be due to significant non-CTL activity since the HLA-A24,28 effectors VOL. 28, 1990 (Table 8 ). In the group which subsequently shed CR-59 virus, the prevaccination geometric mean IFN-y level in supernatant fluids of PBL stimulated in vitro with CR-59 virus-infected autologous PBL was lower than the level in the volunteers who did not shed virus (17.6 versus 69.2 IU/ml [P < 0.05]). There were no differences in geometric mean IFN-y levels between volunteers who subsequently did and did not shed CR-59 virus when the PBL were stimulated in vitro with influenza A/HlN1 virus-infected autologous PBL or with PHA. Also, the prevaccination geometric mean IFN--y level to CR-59 virus in the patients who developed a fourfold nasal wash reciprocal antibody titer rise to CR-59 virus without a concomitant fourfold rise in serum antibody was higher than in those volunteers with a fourfold serum antibody rise postvaccination with CR-59 virus (96.2 versus 30.3 IU/ml [not significant]). Although a causal mechanism is not proven and is unlikely, a higher prevaccination in vitro-induced IFN--y level was associated with a less severe vaccine virus infection manifested by lack of virus shedding or lack of systemic antibody response. There was no significant correlation by linear regression and the Kendall Tau test between IFN--y levels and concomitant percent specific lysis by the corresponding effector PBL against autologous target cells infected with influenza A virus homologous to the virus used to stimulate the effector PBL. (5, 18, 20, 22) . CD4+ HLA class Il major histocompatibility complex-restricted clones with specificity for viral M protein and nucleoprotein with crossreactivity against heterosubtypic influenza A viruses have also been described previously (13 (11, 12, 23) . The major effect of higher minimum release is to reduce the sensitivity of detection of target cell lysis if present and reduce the calculated percent specific lysis value reported. The ranges of both minimum and maximum release were wide, but the mean percent minimum release was similar before and after vaccination for each influenza A virus-infected target cell population and similar between target cell populations for all determinations in the study. Not excluded was the possibility that the influenza A virus-infected stimulator cells added to the effector cell cultures later interfered with the cytotoxicity assay by serving as cold, unlabeled targets. Our method of in vitro stimulation of effector cells was the same as that reported in the literature (11, 12, 22, 23) . In addition, it is known that influenza A virus infection of monocytes and lymphocytes is abortive without the production of new infectious virions so that no more than the initially infected stimulator cells could have been infected in the effector cell cultures (24, 30) . If any of these stimulator cells were still present after 7 days of incubation and if they interfered with effector cell recognition and lysis of radiolabeled target cells, this could have reduced the sensitivity of the assay, but it was a constant factor throughout the study.
The different responses to the live-attenuated and inactivated virus vaccines suggest a clinical advantage for the live-attenuated virus if these differences were notjust simply due to the different viral subtypes in the two vaccines. A broader, cross-reactive cytotoxic T-cell response has also been reported following live virus infection compared with inactivated virus injection in the murine model (3, 27, 34 (19) . This provides evidence for the possible clinical importance of cross-reactive cytotoxic T cells and the desirability of their induction by an influenza A virus vaccine.
Human influenza A virus-specific, HLA-restricted cytotoxic T-cell activity is stimulated by in vivo administration of live-attenuated influenza A virus, wild-type influenza A virus, and inactivated influenza A virus in young adults (11, 29) . In young adults, in vitro inducible cytotoxic T-cellmediated percent specific lysis of autologous target cells infected with influenza A HlNi virus of at least 10% correlated with protection from experimental wild-type influenza A HlNi virus infection manifested by reduced viral shedding but not reduced symptoms of viral infection (23 whether a specific level of percent specific lysis in their study is directly comparable to the same numerical level in our study with respect to correlation with protection from challenge virus was not determined. Also, it is not well established what constitutes a significant rise in percent specific lysis in the individual patient in response to vaccination.
Ennis et al. (11) reported that peak in vitro inducible cytotoxicity occurred in young healthy adults 14 days after vaccination with live-attenuated and inactivated influenza A virus vaccines. However, they did not report whether there were differences in the induction of cross-reactive cytotoxicity against heterosubtypic influenza A virus-infected autologous target PBL with one mode of vaccination compared with the other. Virus-infected target cells showing certain HLA class I antigens (Ai, A9, and B8) were less susceptible to lysis by HLA-matched cytotoxic T cells than target cells which matched effectors at other HLA loci.
The live-attenuated, cold-adapted, temperature-sensitive reassortant viruses retain their internal genes (encoding PA, M protein, PB2, and PB1) from the cold-adapted parent influenza A virus and acquire the RNA segments which encode the HA and NA glycoproteins from the wild-type virus (32) . There may be antigenic differences in internal proteins among wild-type influenza A viruses and the donor cold-adapted influenza A parent virus. Since cross-reactive cytotoxic T cells are often directed against internal proteins, the live-attenuated virus may not always induce a cytotoxic T-cell response against the contemporary wild-type influenza A virus strains.
Mean IFN--y levels in supernatant fluids of effector PBL cultures did not increase significantly postvaccination in either of our vaccinee groups. IFN--y levels did not correlate with the concomitant effector cell killing of infected autologous target cells. A higher prevaccination IFN-y level, however, was associated with a less severe CR-59 vaccine virus infection manifested by lack of viral shedding and lack of a serum anti-influenza antibody titer rise. This cannot be considered a causal mechanism, since IFN--y was measured after 7 days of in vitro culture. The ability of PBL to produce IFN--y in response to in vitro stimulation may, however, be a marker for an immunologic mechanism which resulted in the less severe vaccine virus infection. Yamada et al. (37) , using methods similar to ours, reported IFN-y levels correlated with cytotoxic T-cell activity by in vitro-stimulated PBL collected at one time point from 12 
